These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17118612)

  • 1. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays.
    Jaber A; Baker M
    J Pharm Biomed Anal; 2007 Mar; 43(4):1256-61. PubMed ID: 17118612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Rebif new formulation story: it's not trials and error.
    Jaber A; Driebergen R; Giovannoni G; Schellekens H; Simsarian J; Antonelli M
    Drugs R D; 2007; 8(6):335-48. PubMed ID: 17963425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis.
    Bartholomé EJ; Willems F; Crusiaux A; Thielemans K; Schandené L; Goldman M
    Acta Neurol Belg; 1999 Mar; 99(1):44-52. PubMed ID: 10218092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls.
    Vanderlocht J; Hendriks JJ; Venken K; Stinissen P; Hellings N
    J Neuroimmunol; 2006 Aug; 177(1-2):189-200. PubMed ID: 16797728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis.
    Bellomi F; Muto A; Palmieri G; Focaccetti C; Dianzani C; Mattei M; Jaber A; Antonelli G
    New Microbiol; 2007 Jul; 30(3):241-6. PubMed ID: 17802901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.
    Chen M; Chen G; Nie H; Zhang X; Niu X; Zang YC; Skinner SM; Zhang JZ; Killian JM; Hong J
    Eur J Immunol; 2009 Sep; 39(9):2525-36. PubMed ID: 19670379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis.
    Hedegaard CJ; Krakauer M; Bendtzen K; Sørensen PS; Sellebjerg F; Nielsen CH
    Clin Immunol; 2008 Oct; 129(1):80-9. PubMed ID: 18653385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
    Meager A; Das RG
    J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
    Giovannoni G; Barbarash O; Casset-Semanaz F; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Mult Scler; 2009 Feb; 15(2):219-28. PubMed ID: 18755819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early use of interferon beta patients with multiple sclerosis.
    Bosley EB; Capildeo R
    Int J Clin Pract Suppl; 2002 Sep; (131):17-22. PubMed ID: 12564808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
    Ahn JS; Krishnadas DK; Agrawal B
    Int Immunol; 2007 Mar; 19(3):227-37. PubMed ID: 17289657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
    Leppert D; Waubant E; Bürk MR; Oksenberg JR; Hauser SL
    Ann Neurol; 1996 Dec; 40(6):846-52. PubMed ID: 9007089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenic dendritic cells pulsed with Ixodes ricinus tick saliva prime naive CD4+T to induce Th2 cell differentiation in vitro and in vivo.
    Mejri N; Brossard M
    Int Immunol; 2007 Apr; 19(4):535-43. PubMed ID: 17344202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.